TTNP Titan Pharmaceuticals, Inc. Year-over-year net earnings per share growth for the last 12 months

Public company logo of Titan Pharma (TTNP)

Titan Pharmaceuticals is facing the depletion of legacy product resources, necessitating a structural update. However, the commercialization of ProNeura and the expansion of the partner clinic network are driving margin growth. The quarterly EPS trend on this GURU.Markets chart clearly links business efficiency to the share price, where the value of 72.40 reflects the metric's balance. Meanwhile, industry behemoths dominating the drug delivery systems segment are creating pressure.

Titan Pharmaceuticals Inc. (TTNP) - Year-over-year net earnings per share change for the last twelve months from 07/04/2022 to 10/18/2025

TTNP (Titan Pharmaceuticals, Inc.): analytical breakdowns and indicator data

- market value and analyst target forecast:
Summary company analysis:titanpharm.com, TTNP
Flagship merchandise of titanpharm.com

The assessment of Titan Pharmaceuticals (TTNP) business resilience is based on an analysis of net earnings per share dynamics, which measures the actual efficiency of capital generation per quarter relative to previous periods. By analyzing the quarterly EPS change scale, an investor can see the conversion of ProNeura's technological advantage into financial results, separating fundamental implant sales growth from market price volatility.

Who Titan Pharmaceuticals competes with

Indivior Corp (INDV) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Collegium Pharmaceutical Inc|CRON (thecronosgroup.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth canopygrowth.com|Quarterly EPS earnings growth HITI|ACB (Aurora Cannabis, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ACHV (Achieve Life Sciences, Inc)|Skye Bioscience (SKYE) - Earnings per share growth in annualized terms for the last twelve months|Anebulo Pharmaceuticals - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months InterCure|NTRB: Quarterly EPS earnings growth|NSRX - Year-over-year net earnings per share change for the last twelve months|IGC (IGC Pharma Inc) - Quarterly EPS earnings growth|MIRA Pharmaceuticals - Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth FLGC|IM Cannabis - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth ADIL (Adial Pharmaceuticals)|Artelo - Year-over-year earnings per share growth for the last twelve months|ensysce.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Greenlane Holdings|inmedpharma.com (INM) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months AKAN|Year-over-year earnings per share growth for the last twelve months Enveric Corp|Earnings per share growth in annualized terms for the last twelve months brightgreen.us BGXX|Year-over-year net earnings per share growth for the last 12 months HPCO (Hempacco Co Inc.)